Barbara Steblaj

Dr. Barbara Steblaj

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2023 in Frontiers in Veterinary Science
Verified
Journal Article
Open access
BSBarbara Steblaj
Barbara Steblaj
JGJasmin Galli
Jasmin Galli
PTPaul Torgerson
Paul Torgerson
AKAnnette Kutter
Annette Kutter
Introduction: The aim of this retrospective study was to determine whether there is an association between leukoreduction of packed red blood cell (pRBC) units and reduction of clinically observed transfusion reactions (TR), particularly febrile non-haemolytic transfusion reactions (FNHTR), and better outcomes in dogs. Secondary aims were to evaluate the effects of other factors suspected to influence transfusion reaction frequency or survival, including crossmatching, use of immunosuppressive drugs, and age and number of the blood products being administered.Materials and methods: Medical data on dogs transfused with leukocyte-reduced (LR) and non-leukocyte-reduced (N-LR) pRBC units at the Animal Hospital Zürich, University of Zürich, Switzerland between January 1, 2007, and December 17, 2018 were searched. Before 2014, only N-LR blood were transfused. After 2014, both LR and N-LR blood were available.Results: A total of 339 canine patients were transfused with 413 pRBC units; 30.5% (126/413) were LR units and 69.5% (287/413) were N-LR. Data collected from medical records was analyzed using univariate and multivariate logistic regression. In the present study, TR occurred in 19.8% of pRBC units (25/126) with LR and in 17.7% (51/287) of pRBC with N-LR; p > 0.05. FNHTR occurred in 6.3% of pRBC units (8/126) with LR and in 4.5% (13/287) of those with N-LR; p > 0.05. There was no correlation between the occurrence of TR and discharge from hospital (p > 0.05). Crossmatching, immunosuppressive therapy, and age of the blood product were not associated with the frequency of TR; p > 0.05 for all. The duration of survival days was not related to the number of transfusions dogs received.Discussion: In the present study, the leukocyte-depletion of transfused pRBC units was not associated with fewer TR nor to fewer FNHTR compared to N-LR units. Discharge of dogs from hospital was not dependent on the occurrence of TR.

23 September 2023 in Animals
Verified
Journal Article
Open access
PDF file
ARAna Rostaher
Ana Rostaher
NFNina Fischer
Nina Fischer
AVAlessio Vigani
Alessio Vigani
BSBarbara Steblaj
Barbara Steblaj
FMFranco Martini
Franco Martini
MKMitja Kosnik
Mitja Kosnik
Hymenoptera allergens are the main triggers for anaphylaxis in susceptible dogs and humans. Hymenoptera venom specific immunotherapy (VIT), the only disease-modifying treatment, has the potential to prevent future life-threatening reactions in human patients. Prospective clinical data on VIT efficacy in dogs are currently lacking. Therefore, the aim of this study was to show that VIT is not only safe but also efficacious in preventing anaphylaxis in dogs allergic to Hymenoptera. This uncontrolled prospective clinical trial included 10 client-owned dogs with a history of anaphylaxis following repeated Hymenoptera stings. The sensitization to bee and wasp allergens was demonstrated by intradermal testing (IDT) and allergen-specific IgE serology. For VIT induction (induction phase), dogs received a shortened rush immunotherapy protocol with aqueous allergens, which was then followed by monthly injections of 100 µg of alum-precipitated allergen (maintenance phase). VIT efficacy was determined by observing patients’ clinical reactions to re-stings. No systemic adverse events were seen during the induction and maintenance phases. From the seven re-stung dogs, only one developed a mild angioedema at the site of the sting; the remaining dogs were asymptomatic. These results show that VIT represents a safe and effective treatment option for Hymenoptera-allergic dogs.

11 April 2022 in Veterinary Anaesthesia and Analgesia
Verified
Journal Article
Open access
BSBarbara Steblaj
Barbara Steblaj
ICIvo Campagna
Ivo Campagna
SHSonja Hartnack
Sonja Hartnack
AKAnnette P N Kutter
Annette P N Kutter
To investigate the effects of intramuscularly administered acepromazine or dexmedetomidine on buccal mucosa microcirculation in Beagle dogs. Experimental, blinded, crossover study. A group of seven Beagle dogs aged 7.5 ± 1.4 years (mean ± standard deviation). Microcirculation was assessed on buccal mucosa using sidestream dark field videomicroscopy. After baseline measurements, 5 μg kg-1 dexmedetomidine or 30 μg kg-1 acepromazine were administered intramuscularly. After 10, 20 and 30 minutes, measurements were repeated. At 40 minutes after premedication, anaesthesia was induced with propofol intravenously and maintained with isoflurane. Measurements were repeated 50, 60 and 65 minutes after the injection of the investigated drugs. Analysed microcirculatory variables were: Perfused de Backer density, Perfused de Backer density of vessels < 20 μm, Proportion of perfused vessels and Proportion of perfused vessels < 20 μm. Heart rate (HR), systolic, diastolic (DAP) and mean (MAP) arterial pressures were recorded at the same time points. Macro- and microcirculatory variables were analysed using a linear mixed model with baseline as a covariate, treatment, trial period and repetition as fixed effects and time and dog as random effect. Results are presented as effect size and confidence interval; p values < 0.05 were considered significant. After acepromazine, Perfused de Backer density was greater during sedation and anaesthesia [3.71 (1.93-5.48 mm mm-2, p < 0.0001) and 2.3 (0.86-3.75 mm mm-2, p < 0.003)], respectively, than after dexmedetomidine. HR was significantly lower, whereas MAP and DAP were significantly higher with dexmedetomidine during sedation and anaesthesia (p < 0.0001 for all) compared with acepromazine. The sedative drugs tested exerted a significant effect on buccal mucosal microcirculation with a higher Perfused de Backer density after the administration of acepromazine compared with dexmedetomidine. This should be considered when microcirculation is evaluated using these drugs.

28 August 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
ARAna Rostaher
Ana Rostaher
NFNina Fischer
Nina Fischer
AVAlessio Vigani
Alessio Vigani
BSBarbara Steblaj
Barbara Steblaj
FMFranco Martini
Franco Martini
MKMitja Kosnik
Mitja Kosnik
Hymenoptera allergens are the main triggers for anaphylaxis in susceptible dogs and humans. Hymenoptera venom specific immunotherapy (VIT), the only disease-modifying treatment, has the potential to prevent future life-threatening reactions in human patients. Prospective clinical data on VIT efficacy in dogs are currently lacking. Therefore, the aim of this study was to show that VIT is not only safe but also efficacious in preventing anaphylaxis in dogs allergic to Hymenoptera. This uncontrolled prospective clinical trial included 10 client-owned dogs with a history of anaphylaxis following repeated Hymenoptera stings. The sensitization to bee and wasp allergens was demonstrated by intradermal testing (IDT) and allergen-specific IgE serology. For VIT induction (induction phase), dogs received a shortened rush immunotherapy protocol with aqueous allergens, which was then followed by monthly injections of 100 g of alum-precipitated allergen (maintenance phase). VIT efficacy was determined by observing patients’ clinical reactions to re-stings. No systemic adverse events were seen during the induction and maintenance phase. From the seven re-stung dogs, only one developed a mild angioedema at the site of the sting; the remaining dogs were asymptomatic. These results show that VIT represents a safe and effective treatment option for Hymenoptera-allergic dogs.

24 July 2023 in Research in Veterinary Science
Verified
Journal Article
Open access
BSBarbara Steblaj
Barbara Steblaj
AKA.P.N. Kutter
A.P.N. Kutter
MSM. Stirn
M. Stirn
SDS. Daminet
S. Daminet
AMA. Major
A. Major
EZE. Zini
E. Zini
Sepsis of Gram negative bacterial origin results in lipopolysaccharide-induced endotoxemia. This often leads to acute kidney injury (AKI) and its recognition remains a challenge and delays treatment. As renal damage occurs before a rise in serum creatinine is detected, new early biomarkers of kidney injury need to be explored. The aim of this study was to determine changes in serum parameters of renal function and urine biomarkers of renal injury. This was a descriptive study. Endotoxemia was induced intravenously in six anaesthetized Beagles (T1). To achieve normotension, dogs received fluids (T2), followed by a continuous infusion of noradrenaline and dexmedetomidine or 0.9% NaCl (T3). Ten minutes later, the dogs received fluids (T4) and noradrenaline and dexmedetomidine or 0.9% NaCl in a crossover manner (T5). At each timepoint, blood and urine were collected for serum creatinine, urea, symmetric dimethylarginine, urine protein/creatinine (UPC) ratio, urine neutrophil-gelatinase-associated lipocalin (U-NGAL), U-NGAL/creatinine ratio, urine clusterin (U-clusterin) and U-clusterin/creatinine ratio. Data were analyzed using a mixed-effect model taking into account time and stage of veterinary AKI (VAKI). Three of six dogs had a VAKI stage ≥1; one with anuria and elevated creatinine. Serum creatinine (P < 0.001), U-NGAL/creatinine ratio (P = 0.01) and U-clusterin/creatinine ratio increased over time (P < 0.01). The UPC ratio (mean (range) 0.68 (0.35-2.3) versus 0.39 (0.15-0.71) P < 0.01) and U-NGAL (3164 pg/mL (100-147,555) versus 100 (100-14,524), P = 0.01) were higher in VAKI stage ≥1 versus stage 0, respectively. Endotoxemia induced VAKI stage ≥1 in half of the dogs. Repeated measurement of selected parameters could detect AKI early.

13 April 2026 in Veterinary Anaesthesia and Analgesia
Verified
Journal Article
Open access
FGFederico Gianolli
Federico Gianolli
BSBarbara Steblaj
Barbara Steblaj
CGChristina A. Gruell
Christina A. Gruell
AKAnnette P N Kutter
Annette P N Kutter
To compare macrocirculatory effects of haemorrhage followed by fluid resuscitation with Plasma-Lyte A (PA) or Ringer's Lactate (RL) crystalloid solution in dogs under sevoflurane anaesthesia. Single-centre, randomised, blinded, experimental study. A group of 12 adult, healthy, intact, purpose-bred Beagle dogs. Dogs were instrumented under sevoflurane anaesthesia. Heart rate, cardiac output (CO), and mean arterial blood pressure (MAP) were measured at baseline, after removing 30 mL kg-1 of blood over 15 minutes [hypovolaemia (HV)], and after each of two boluses (B1 and B2) of either 10 mL kg-1 PA or RL administered intravenously over 10 minutes. Data were compared using a linear mixed model with group and time points as fixed factors and dogs as a random factor, and corrections for multiple comparisons. A p value < 0.05 was considered significant. There were no significant differences between treatments. Compared with HV, CO increased in both groups at B1: RL [0.57 (0.23-0.91) L minute-1 (estimated difference ± 95% confidence interval), p < 0.001] and PA [0.37 (0.03-0.7) L minute-1, p = 0.030], and at B2: RL [0.88 (0.54-1.2), p < 0.001] and PA [0.66 (0.23-0.91) L minute-1, p < 0.001]. The increase of MAP in RL was significant at B1 [15 (1-29) mmHg, p < 0.028] and B2 [16 (2-30) mmHg, p < 0.016] compared with HV, while MAP in PA was not significantly different at B1 [3 (-11 to 17) mmHg, p = 0.995] and B2 [4 (-9 to 18) mmHg, p = 0.943] compared with HV. In this small experimental study, both fluids tested led to a clinically significant increase in CO. No consistent increase in MAP was observed across fluid types. Alterations in MAP should not be used as a surrogate for flow variables to assess fluid responsiveness.